Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Marizomib |
| Synonyms | |
| Therapy Description |
Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470, PMID: 29076150). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Marizomib | NPI-0052|ML 858|Salinosporamide A|Salinosporin A | Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470, PMID: 29076150). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04341311 | Phase I | Marizomib + Panobinostat Marizomib | Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG) | Terminated | USA | 0 |
| NCT03727841 | Phase II | Marizomib | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | Terminated | USA | 0 |